Executives at BIO 2026 said biotech partnerships, licensing deals, and acquisitions remain strong as companies adapt their business development strategies to navigate policy, regulatory, […]
BIO 2026: Biotech dealmakers navigate uncertainty, pursue opportunities Read More »
From drug discovery to target identification, biotech leaders explored where AI is delivering results today, why data quality matters, and how companies can successfully
BIO 2026: Where AI is delivering – and where biotech must go next Read More »
BIO’s partnering platform connects biotechnology companies, investors, and strategic partners, making the BIO International Convention one of the industry’s largest business development events. A
BIO 2026: The business of biotech runs on partnerships Read More »
BIO 2026 brings together 20,000 biotechnology leaders in San Diego for four days of partnering, policy discussions, AI, and innovation as the industry celebrates
BIO 2026 begins in San Diego, marking 50 years of biotech innovation Read More »
The Reagan-Udall Foundation for the FDA just released a new report on strengthening early-stage drug development in the United States. The report reflects insights
New report details how U.S. can maintain biotech competitiveness Read More »
“AI systems will likely have a central role over the next several years in almost every component of the biotech ecosystem,” says Joe Franklin,
BIO 2026: What to know about the AI Summit Read More »
For decades, the United States has led the world in developing new medicines, turning scientific breakthroughs into treatments that save and improve lives. But
As policy ecosystem threatens biotech, new treatments could drop by over 50% in 20 years Read More »
Patient advocates are praising Virginia Gov. Abigail Spanberger’s May 19 veto of Prescription Drug Affordability Board (PDAB) legislation (HB 483 and SB 271), arguing
Patient groups praise Virginia PDAB veto Read More »
The last time the BIO International Convention was in San Diego, in 2024, Ram May-Ron of the non-dilutive funding specialists FreeMind Group began discussing
BIO 2026: Partnering meetings fill up for industry’s biggest gathering Read More »
Strengthening America’s biopharma manufacturing base and biotechnology leadership are goals both BIO and the Trump administration share. But as companies work to advance those
Section 232 tariff uncertainty remains high as onshoring plan deadline looms Read More »
